Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03555682 · ClinicalTrials.gov registry record · NA
2-HOBA: Multiple Dosing Study in Healthy Humans
A NA study, sponsored by Metabolic Technologies.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03555682: Completed NA study, sponsored by Metabolic Technologies.
NCT03555682 is a NA study that has completed, run by Metabolic Technologies. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03555682, a NA study, has completed, sponsored by Metabolic Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test how well people tolerate a new dietary ingredient called 2-HOBA and how it is metabolized in the body. 2-HOBA is a compound that occurs naturally in buckwheat seeds. This dietary ingredient has been used in animal studies, and single doses have been tolerated well when given to a small group of healthy people. In this study we will test how well people tolerate taking 2-HOBA over 2 weeks and how it is metabolized by the body.
Primary Outcome
Tolerability will be assessed through adverse event reporting compared with the placebo group (Comparison of number of AE in treated group to number of AE in placebo group).
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT 2-HOBA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-05-23 |
| Est. Completion | 2019-05-10 |
| Phase | NA |
What the finished NCT03555682 record still lists
NCT03555682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03555682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03555682 about?
NCT03555682 is a clinical study titled "2-HOBA: Multiple Dosing Study in Healthy Humans". The purpose of this study is to test how well people tolerate a new dietary ingredient called 2-HOBA and how it is metabolized in the body. 2-HOBA is a compound that occurs naturally in buckwheat seeds. This dietary ingredient has been used in animal studies, and single doses have been tolerated wel...
What is the current status of trial NCT03555682?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-05-23. Estimated completion is 2019-05-10.
What interventions are being tested in trial NCT03555682?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), 2-HOBA (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03555682?
This trial is sponsored by Metabolic Technologies, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03555682's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI